Scientific discoveries made in previous EC funded research programs on the lactic acid bacteria (LAB) have shown that there is considerable potential to develop products based on the oral delivery of vaccine and therapeutic agents using harmless commensally LAB. The aim is to harness this potential by developing and testing prototype LAB-based products for vaccination, prevention and treatment of type I allergy, treatment of a metabolic disorder and delivery of a therapeutic antioxidant. This multifaceted strategy for exploitation is underpinned by research on LAB fermentation and technological innovations that will enhance the efficiency of LAB delivery systems.
Funding SchemeCSC - Cost-sharing contracts
14220 Praha 4
CH5 2NT Deeside
6710 BA Ede Gld